- •FCS is a rare genetic disorder that results in LPL activity deficiency.
- •The LPL activity method is not standardised.
- •Cut-off points to consider LPL activity deficiency must be stablished.
- •A cut-off value of 25 % of the mean LPL activity of a MCS cohort has been defined.
- •A comprehensive workflow for FCS diagnosis is provided in this study.
Activity assays for lipoprotein lipase (LPL) are not standardised for use in clinical settings. Objective: This study sought to define and validate a cut-off points based on a ROC curve for the diagnosis of patients with familial chylomicronemia syndrome (FCS). We also evaluated the role of LPL activity in a comprehensive FCS diagnostic workflow.
A derivation cohort (including an FCS group (n = 9), a multifactorial chylomicronemia syndrome (MCS) group (n = 11)), and an external validation cohort (including an FCS group (n = 5), a MCS group (n = 23) and a normo-triglyceridemic (NTG) group (n = 14)), were studied. FCS patients were previously diagnosed by the presence of biallelic pathogenic genetic variants in the LPL and GPIHBP1 genes. LPL activity was also measured. Clinical and anthropometric data were recorded, and serum lipids and lipoproteins were measured. Sensitivity, specificity and cut-offs for LPL activity were obtained from a ROC curve and externally validated.
All post-heparin plasma LPL activity in the FCS patients were below 25.1 mU/mL, that was cut-off with best performance. There was no overlap in the LPL activity distributions between the FCS and MCS groups, conversely to the FCS and NTG groups.
We conclude that, in addition to genetic testing, LPL activity in subjects with severe hypertriglyceridemia is a reliable criterium in the diagnosis of FCS when using a cut-off of 25.1 mU/mL (25% of the mean LPL activity in the validation MCS group). We do not recommend the NTG patient based cut-off values due to low sensitivity.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Clinical Lipidology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia.Atherosclerosis. 2019; 283 (November 2018): 137-142https://doi.org/10.1016/j.atherosclerosis.2018.12.019
- The familial chylomicronemia syndrome.Endocrinol Metab Clin North Am. 1998; 27: 551-567https://doi.org/10.1016/S0889-8529(05)70025-6
- Familial Chylomicronemia (Type I Hyperlipoproteinemia) Due to a Single Missense Mutation in the Lipoprotein Lipase Gene.1991 (Vol 87)
- Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia.J Intern Med. 2020; 287: 340-348https://doi.org/10.1111/joim.13016
- Arteriosclerosis, thrombosis, and vascular biology ATVB NAMED LECTURE REVIEW 2019 george lyman duff memorial lecture three decades of examining DNA in patients with dyslipidemia.Arterioscler Thromb Vasc Biol. 2020; 40: 1970-1981https://doi.org/10.1161/ATVBAHA.120.313065
- Assays of Lipolytic Enzymes.2001https://doi.org/10.1385/1592592317 (Vol 155)
- Diagnostic value of post-heparin lipase testing in detecting common genetic variants in the LPL and LIPC genes.Eur J Human Gen. 2009; 17: 1386-1393https://doi.org/10.1038/ejhg.2009.61
- Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study.J Clin Lipidol. 2018; 12 (.e5): 1234-1243https://doi.org/10.1016/j.jacl.2018.05.013
- Current diagnosis and management of primary chylomicronemia.J Atheroscler Thromb. 2021; 28: 1-22https://doi.org/10.5551/jat.RV17054
- Molecular basis of the familial chylomicronemia syndrome in patients from the national dyslipidemia registry of the spanish atherosclerosis society.J Clin Lipidol. August 2018; https://doi.org/10.1016/j.jacl.2018.07.013
Protocolo farmacoclínico del uso de volanesorsén en el tratamiento del síndrome de quilomicronemia familiar en el sistema nacional de salud. 2022.
- Standards for global cardiovascular risk management arteriosclerosis.Clinica e Investigacion en Arteriosclerosis. 2019; 31: 1-43https://doi.org/10.1016/j.arteri.2019.03.004
- Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis.BMC Gastroenterol. 2009; 9: 1-10https://doi.org/10.1186/1471-230X-9-46
- Molecular basis of the familial chylomicronemia syndrome in patients from the national dyslipidemia registry of the spanish atherosclerosis society.J Clin Lipidol. 2018; 12 (e3): 1482-1492https://doi.org/10.1016/j.jacl.2018.07.013
- Evaluation of the chylomicron-TG to VLDL-TG ratio for type I hyperlipoproteinemia diagnostic.Eur J Clin Invest. 2020; (June): 1-9https://doi.org/10.1111/eci.13345
- Post-heparin lipolytic activity in acute renal failure.Clin Nephrol. 1985; 23: 289-293
- Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins.Arteriosclerosis, Thrombosis, Vascular Biol. 1995; 15: 1086-1093https://doi.org/10.1161/01.ATV.15.8.1086
Dean AG, Sullivan KM, Soe MM, Mir RA, Kulkarni H. Openepi Web Page.
- Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects.PLoS One. 2014; 9https://doi.org/10.1371/journal.pone.0096482
- Determination of lipoprotein lipase activity using a novel fluorescent lipase assay.J Lipid Res. 2011; 52: 826-832https://doi.org/10.1194/jlr.D010744
- Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an “FCS score.Atherosclerosis. 2018; 275: 265-272https://doi.org/10.1016/j.atherosclerosis.2018.06.814
- Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue.Molecular Metabolism. 2020; 40101033https://doi.org/10.1016/j.molmet.2020.101033
- Physiological regulation of lipoprotein lipase.Biochimica et Biophysica Acta - Mol Cell Biol Lipids. 2014; 1841: 919-933https://doi.org/10.1016/j.bbalip.2014.03.013
- Severe hypertriglyceridemia is primarily polygenic.J Clin Lipidol. 2019; 13: 80-88https://doi.org/10.1016/j.jacl.2018.10.006
- Chylomicronemia Syndrome. 1982; 66: 1982
- Diagnostic algorithm for familial chylomicronemia syndrome.Atheroscler Suppl. 2017; 23: 1-7https://doi.org/10.1016/j.atherosclerosissup.2016.10.002
- Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.Nat Rev Endocrinol. 2010; https://doi.org/10.1038/nrendo.2010.50
- A case of severe acquired hypertriglyceridemia in a 7-year-old girl.J Clin Lipidol. 2017; 11: 1480-1484https://doi.org/10.1016/j.jacl.2017.08.003
- GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia.J Clin Lipidol. 2017; 11: 964-971
- Clinical and biochemical features of different molecular etiologies of familial chylomicronemia.J Clin Lipidol. 2018; 12: 920-927https://doi.org/10.1016/j.jacl.2018.03.093
- ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition.J Lipid Res. 2021; 62100068https://doi.org/10.1016/J.JLR.2021.100068
- Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia.Arterioscler Thromb Vasc Biol. 2005; 25: 411-417https://doi.org/10.1161/01.ATV.0000153087.36428.dd
Published online: January 25, 2023
Accepted: January 18, 2023
Received: September 16, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 National Lipid Association. Published by Elsevier Inc. All rights reserved.